Aptevo Therapeutics Inc (APVO)

Jun 09, 2026

Aptevo and Niowave Partner to Advance Radiopharmaceutical Cancer Therapies - citybuzz -

Jun 09, 2026

Jun 09, 2026

As Big Pharma Bets On Radiopharmaceuticals, Aptevo And Niowave Join Forces To Advance Novel Targeted Cancer Therapeutics In The $17B+ Oncology Category - NewMediaWire

Jun 09, 2026

Jun 05, 2026

Aptevo reports 87% clinical benefit rate in AML trial - Investing.com

Jun 05, 2026

May 31, 2026

- The Legal Advocate

May 31, 2026

May 30, 2026

Aptevo Therapeutics (APVO) Slips 1.43% as Shares Test Key Support Near $4.66Butterfly Setup - The Legal Advocate

May 30, 2026

May 29, 2026

Aptevo Therapeutics Dip Continues as Stock Consolidates Near Key SupportBuffered ETF - The Legal Advocate

May 29, 2026

May 29, 2026

Aptevo Therapeutics (APVO) Slides Lower as Support Level Comes Into FocusFibonacci Retracement - The Legal Advocate

May 29, 2026

May 29, 2026

APVO Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Faces HeadwindsPretax Income Report - newsline.com

May 29, 2026

May 28, 2026

Aptevo Therapeutics (APVO) SVP, CSO files Form 3 reporting zero shares - Stock Titan

May 28, 2026

May 28, 2026

Aptevo names Mary Janatpour as chief scientific officer - Investing.com UK

May 28, 2026

May 28, 2026

Aptevo Therapeutics Names Mary Janatpour Chief Scientific Officer as It Expands Beyond Core Immuno-Oncology Programs - citybiz

May 28, 2026

May 28, 2026

Aptevo names Mary Janatpour as chief scientific officer By Investing.com - Investing.com Nigeria

May 28, 2026

May 28, 2026

Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer - ACCESS Newswire

May 28, 2026

May 28, 2026

Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing - Black Hills Pioneer

May 28, 2026

May 28, 2026

Seattle biotech lands investment, collaboration deal for cancer treatments - The Business Journals

May 28, 2026

May 27, 2026

Aptevo and Niowave Partner to Develop Radiopharmaceuticals; Niowave to Invest in Aptevo - geneonline.com

May 27, 2026

May 27, 2026

Aptevo Forms Strategic Radiopharmaceutical Collaboration with Niowave - TipRanks

May 27, 2026

May 27, 2026

Aptevo Therapeutics (APVO) Forms Strategic Collaboration with Ni - GuruFocus

May 27, 2026

May 27, 2026

APVO Q1 2026 Earnings: EPS Miss Widens as Revenue Remains AbsentEarnings Preview - The Legal Advocate

May 27, 2026

May 27, 2026

Aptevo and Niowave launch radiopharmaceuticals collaboration - The Pharma Letter

May 27, 2026

May 27, 2026

Aptevo, Niowave form 50/50 partnership for cancer drugs By Investing.com - Investing.com Nigeria

May 27, 2026

May 27, 2026

Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, I - PharmiWeb.com

May 27, 2026

May 27, 2026

Aptevo, Niowave form 50/50 partnership for cancer drugs - Investing.com

May 27, 2026

May 27, 2026

Niowave takes 7.9% Aptevo stake in cancer radiopharma tie-up - Stock Titan

May 27, 2026

May 22, 2026

APVO Q1 2026 Earnings: Stock Rises Despite Wider-Than-Expected Loss as Pipeline Progress Takes Center Stage - The Legal Advocate

May 22, 2026

May 21, 2026

APVO Q1 2026 Earnings: Stock Gains Sharply Despite Wider-Than-Expected LossShare Dilution Risk - The Legal Advocate

May 21, 2026

May 21, 2026

Aptevo (APVO) Q1 2026 Earnings: Soft Quarter Raises QuestionsEarnings Miss Alert - Newser

May 21, 2026

May 20, 2026

All you need to know about Aptevo Therapeutics (APVO) rating upgrade to buy - MSN

May 20, 2026

May 20, 2026

All You Need to Know About Aptevo Therapeutics (APVO) Rating Upgrade to Buy - Yahoo Finance

May 20, 2026

May 19, 2026

Aptevo (APVO) Q1 2026 Earnings Miss by Significant: Key TakeawaysEPS Consistency Score - Newser

May 19, 2026

May 14, 2026

Key facts: Aptevo Q1 loss $0.01/sh; mipletamig shows 87% clinical benefit - TradingView

May 14, 2026

May 14, 2026

Roth MKM Maintains Aptevo Therapeutics(APVO.US) With Buy Rating, Maintains Target Price $21 - Moomoo

May 14, 2026

May 13, 2026

Aptevo reports clinical trial results for AML drug candidate By Investing.com - Investing.com India

May 13, 2026

May 13, 2026

Aptevo (APVO) Positioned for Growth with Promising Pipeline and Leadership - GuruFocus

May 13, 2026

May 13, 2026

Aptevo Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 13, 2026

May 13, 2026

Aptevo Therapeutics (NASDAQ: APVO) warns on going concern after $6.7M Q1 loss - Stock Titan

May 13, 2026

May 13, 2026

Strong AML data and $60M equity facility in Aptevo (NASDAQ: APVO) Q1 update - Stock Titan

May 13, 2026

May 13, 2026

Aptevo Therapeutics Updates on Q1 2026 Progress and Leadership T - GuruFocus

May 13, 2026

May 13, 2026

Aptevo reports clinical trial results for AML drug candidate - Investing.com UK

May 13, 2026

May 13, 2026

Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection - ACCESS Newswire

May 13, 2026

May 13, 2026

Leukemia trial hits 81% remission; Aptevo lines up $60M equity line - Stock Titan

May 13, 2026

May 13, 2026

APVO Price Today: Aptevo Therapeutics Inc. Stock Price, Quote & Chart | MEXC - MEXC

May 13, 2026

May 11, 2026

TradingKey - TradingKey

May 11, 2026

May 11, 2026

Number of shareholders of Aptevo Therapeutics, Inc. – GETTEX:AP82 - TradingView

May 11, 2026

May 09, 2026

10-K - SEC.gov

May 09, 2026

May 08, 2026

Aptevo Therapeutics Inc expected to post a loss of $5.60 a shareEarnings Preview - TradingView

May 08, 2026